Pfizer Inc. (PFE) Receives Average Rating of “Hold” from Analysts

Pfizer Inc. (NYSE:PFE) has earned an average recommendation of “Hold” from the twenty-three brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $39.47.

Several equities analysts have recently commented on the company. BMO Capital Markets set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research report on Monday. UBS Group set a $42.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Berenberg Bank set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. Morningstar set a $38.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. Finally, Goldman Sachs Group set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th.

In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Shine Investment Advisory Services Inc. bought a new stake in Pfizer during the second quarter worth $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer in the 2nd quarter valued at $103,000. D. Scott Neal Inc. lifted its stake in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the last quarter. First Dallas Securities Inc. bought a new position in shares of Pfizer in the 4th quarter valued at $118,000. Finally, Delphi Private Advisors LLC lifted its stake in shares of Pfizer by 84.3% in the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 69.87% of the company’s stock.

Pfizer (NYSE PFE) traded up $0.53 during trading on Friday, hitting $34.16. The stock had a trading volume of 47,296,352 shares, compared to its average volume of 24,160,000. Pfizer has a 52 week low of $31.67 and a 52 week high of $39.43. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $203,620.00, a P/E ratio of 9.70, a price-to-earnings-growth ratio of 1.98 and a beta of 0.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter in the prior year, the business earned $0.47 earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. sell-side analysts predict that Pfizer will post 2.95 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.98%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is currently 38.64%.

Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://sportsperspectives.com/2018/02/09/pfizer-inc-pfe-receives-average-rating-of-hold-from-analysts.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply